Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Joliet, Illinois Clinical Trials

A listing of Joliet, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (22) clinical trials

Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy

PRIMARY OBJECTIVES: I. To evaluate and compare the progression free survival rate after randomization in the two treatment arms (nivolumab versus [vs.] observation). SECONDARY OBJECTIVES: I. To determine and compare the overall survival rates in the two arms. II. To determine and compare the incidence of non-relapse mortality in the ...

Phase

2.75 miles

Learn More »

Blinatumomab and Combination Chemotherapy or Dasatinib Prednisone and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

PRIMARY OBJECTIVES: I. To evaluate the 3-year survival rate in elderly patients with newly diagnosed Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL) treated with blinatumomab followed by POMP (prednisone, vincristine sulfate, methotrexate, and mercaptopurine) maintenance. II. To evaluate in a preliminary manner (feasibility study) the safety of dasatinib-steroid based induction followed ...

Phase

2.75 miles

Learn More »

Efficacy and Safety of TD-1473 in Crohn's Disease

A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 12 weeks of induction therapy with TD1473 in subjects with moderately-to-severely active CD. This study includes 3 phases: Screening, Induction, and Active Treatment Extension (ATE). The Induction phase of the study is a ...

Phase

2.75 miles

Learn More »

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

PRIMARY OBJECTIVES: I. To evaluate overall response rate (ORR) with nivolumab in patients with previously treated metastatic squamous cell carcinoma (SCCA) of the anal canal. (Part A) II. To determine an improvement in progression-free survival (PFS) when nivolumab is combined with ipilimumab versus (vs.) nivolumab alone in patients with previously ...

Phase

2.75 miles

Learn More »

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced Recurrent or Metastatic Endometrial Cancer

PRIMARY OBJECTIVES: I. To evaluate the clinical anti-tumor activity of cabozantinib s-malate (XL184 ([cabozantinib]) and nivolumab based on progression free survival (PFS) in patients with advanced, recurrent or metastatic endometrial cancer previously treated with at least one line of platinum-based chemotherapy compared to patients receiving nivolumab alone. SECONDARY OBJECTIVES: I. ...

Phase

2.75 miles

Learn More »

Adavosertib in Treating Patients With SETD2-Deficient Locally Advanced or Metastatic Solid Tumors

PRIMARY OBJECTIVES: I. To determine the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria of adavosertib (AZD1775) in advanced solid tumor malignancies other than clear cell renal cell carcinoma with evidence of biallelic loss of SETD2 using next-generation sequencing panel. II. To determine the objective ...

Phase

2.75 miles

Learn More »

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

PRIMARY OBJECTIVES: I. To evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR). SECONDARY OBJECTIVES: I. To estimate ...

Phase

2.75 miles

Learn More »

Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer

PRIMARY OBJECTIVES: I. To compare the progression free survival (PFS) between two study arms, i.e., olaparib monotherapy (arm 1) and olaparib + atezolizumab in combination (arm 2) based on normal Response Evaluation Criteria in Solid Tumors (RECIST) criteria in patients with locally advanced or metastatic non-HER2-positive breast cancer harboring homologous ...

Phase

3.16 miles

Learn More »

Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

PRIMARY OBJECTIVES: I. To describe the progression-free survival (PFS) of stereotactic body radiation therapy (SBRT) + pembrolizumab (MK-3475) compared to MK-3475 alone in advanced/metastatic Merkel cell carcinoma (MCC) patients. SECONDARY OBJECTIVES: I. To describe the PFS of SBRT + MK-3475 compared to MK-3475 alone across Response Evaluation Criteria in Solid ...

Phase

3.16 miles

Learn More »

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase

8.38 miles

Learn More »